“Screen smarter” and treat less is the message

The March 2013 issue of the AUA News carries a strong message from two leading experts on the early diagnosis and treatment of localized prostate cancer regarding the appropriate use of PSA testing for risk of prostate cancer and consequent follow-up. … READ MORE …

New point of care PSA test … coming soon to your doctor’s office?

According to a media release issued last week by a relatively new company called True Diagnostics, Inc., they hope shortly to be able to introduce a new, “point of care” technical system that can be used to assay PSA levels from a “finger-prick” quantity of blood, thus allowing almost instant assessment of PSA levels in the doctor’s office. … READ MORE …

BMJ clinical review discourages widespread prostate cancer screening

A clinical review in this week’s issue of the British Medical Journal (BMJ) states clearly that “Prostate cancer screening with the PSA blood test results in at most a small reduction in prostate cancer mortality and leads to considerable diagnostic and treatment related harms” and that “Physicians should recommend against PSA screening for prostate cancer.” … READ MORE …

Differing perspectives on prostate cancer testing for healthy men

As fodder for the ongoing discussion about the appropriateness of PSA testing (particularly of younger, healthy men) and risk for prostate cancer, we would draw our reader’s attention to an article from the Annals of Family Medicine just reprinted on the Medscape web site. … READ MORE …

7 months after the USPSTF recommendation on PSA testing of healthy males

Here is a link to story yesterday on MedPage Today about differing perspectives on the U.S. Preventive Services Task Force (USPSTF) recommendation about the appropriateness of annual PSA testing for otherwise healthy men for their risk for prostate cancer — some 7 months after the final USPSTF recommendation was formally released. … READ MORE …

Dr. Peter Scardino on “screening” for risk of prostate cancer

There is an interesting piece just posted on the UroToday web site in which Dr. Peter Scardino (the Chief of Surgery at the Memorial Sloan-Kettering Cancer Center in New York, and the surgeon whose outcome data were used to develop the early versions of the Kattan nomograms) talks about appropriate modern attitudes to “screening” for prostate cancer. … READ MORE …

Use of PSA testing increases by 130 percent in Sweden over 9 years

A new study in European Urology has provided information about expansion of use of the PSA test in Sweden — by some 130 percent — between 2003 and 2011. This despite the fact that (rightly or wrongly) mass population-based screening for prostate cancer is not recommended in Sweden. … READ MORE …

Wasted air in the media and the merits of PSA testing

So for those who simply can’t leave this subject alone, there was a pointless “debate” in today’s Wall Street Journal about the merits of regular PSA testing between Richard Ablin, PhD and Oliver Sartor, MD. … READ MORE …

Patient tools to assist decision-making about PSA tests for risk of prostate cancer

As previously discussed on this blog, on July 16 the American Society of Clinical Oncology (ASCO) issued a provisional clinical opinion or PCO on the merits of screening for prostate cancer (see prior commentary on this PCO). … READ MORE …

Incidence of diagnosis of prostate cancer declines from 2007 to 2009 in USA

According to a brief research letter by Howard, just published in Archives of Internal Medicine, the incidence of prostate cancer diagnosis in men of ≥ 75 years declined significantly after the issuance of the 2008 recommendation by the USPSTF that PSA screening for prostate cancer was not appropriate in men of 75 years and older. … READ MORE …

The AUA’s “toolkit” on the role of PSA in testing for prostate cancer

Some regular readers may want to be keeping an eye on what the American Urological Association (AUA) is providing to its members in response to the recent, final U.S. Preventive Services Task Force recommendation related to the widespread use of PSA testing of healthy men as a method to “screen” for risk of prostate cancer. … READ MORE …

James Eastham on PSA testing and prostate cancer risk

Dr. James Eastham is a highly respected and specialized prostate cancer surgeon who works at the Memorial Sloan-Kettering Cancer Center in New York City. In an interview just published on the OncologySTAT web site, he talks about his views on the appropriate application of the PSA test today in assessment of risk for prostate cancer and management of low-risk disease. … READ MORE …

How one good story may trump a plethora of good data

Some readers may be interested in reviewing an article that appears in Time magazine this week entitled “Why people stick with cancer screening, even when it causes harm.” The article reviews how our experiences and perceptions may color the way we make our individual decisions about things like screening for breast and prostate cancers.

Baseline PSA levels and 10-year risk for a diagnosis of prostate cancer

Earlier, retrospective studies based on Swedish and Danish databases have suggested that men in their 40s with a single PSA level of < 1.0 ng/ml are at low risk for a diagnosis of prostate cancer for up to 30 years after that initial, baseline PSA result. … READ MORE …

AHRQ responds to letter from Prostate Cancer Roundtable

Members of the Prostate Cancer Roundtable have received a letter from the Agency for Healthcare Research and Quality (AHRQ) addressing issues raised by the Roundtable members about the draft USPSTF recommendations on use of the PSA test in screening for risk of prostate cancer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers